Acousia Therapeutics Competitors and Similar CompaniesClear all
Acousia Therapeutics's competitors and similar companies include Molecular Partners, Y-mAbs Therapeutics, Brii Biosciences and BioSpecifics Technologies.
 Acousia Therapeutics Acousia Therapeutics is a biotech company working to identify small molecules for treatment of hearing loss. |  Molecular Partners Molecular Partners is a company that develops biopharmaceutical products for serious diseases. |  Y-mAbs Therapeutics Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets. |  Brii Biosciences Brii Biosciences researches and develops medicines for the treatment of chronic illnesses with significant burdens, including infectious diseases, liver and lung diseases, and other illnesses. |  BioSpecifics Technologies BioSpecifics Technologies is a biopharmaceutical company that has developed injectable collagenase for different clinical indications. | |
Founding Date | Founding Date 2017 | Founding Date 2004 | Founding Date 2014 | Founding Date 2018 | Founding Date 1957 |
Type | Type Private | Type Public | Type Public | Type Private | Type Public |
Tags | |||||
Locations | Locations Tübingen, DE HQ | Locations Zürich-Schlieren, CH HQ Cambridge, US Concord, US | Locations New York, US HQ Copenhagen, DK Nutley, US | Locations CN HQ Beijing, CN Durham, US San Francisco, US San Mateo, US | Locations Lynbrook, US HQ Wilmington, US |
Employees | Employees N/A | Employees 158 | Employees 3239% increase | Employees 8510% decrease | Employees 740% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 657 m | Valuation ($) N/A | Valuation ($) 650.2 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $87.7m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) $38.2m (FY, 2019) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $15m (FY, 2024) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $72.7m (FY, 2024) | Gross profit N/A | Gross profit N/A |
Net income | Net income N/A | Net income (CHF61.7m) (FY, 2025) | Net income ($29.7m) (FY, 2024) | Net income N/A | Net income $24.5m (FY, 2019) |
Funding | |||||
Latest funding round | Latest funding round $ 12m (about 8 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 155m (about 5 years ago) | Latest funding round N/A |
Total funding raised | Total funding raised $ 14.6m | Total funding raised N/A | Total funding raised $ 80m | Total funding raised $ 415m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Molecular Partners
HQ
Zürich-Schlieren, CH
Employees
158
Molecular Partners is a company that develops biopharmaceutical products for serious diseases.
View companyY-mAbs Therapeutics
HQ
New York, US
Employees
32↑ 39% increase
Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets.
View companyBrii Biosciences
HQ
CN
Employees
85↓ 10% decrease
Brii Biosciences researches and develops medicines for the treatment of chronic illnesses with significant burdens, including infectious diseases, liver and lung diseases, and other illnesses.
View companyBioSpecifics Technologies
HQ
Lynbrook, US
Employees
7↑ 40% increase
BioSpecifics Technologies is a biopharmaceutical company that has developed injectable collagenase for different clinical indications.
View company